表紙
市場調查報告書
商品編碼
972020

疫苗銷售市場(2020-2030年):疾病類型,病毒性疾病,細菌性疾病,疫苗類型,分銷渠道,年齡段,區域預測,競爭狀況,COVID-19影響分析,主要公司概況

Vaccines Sales Market Report 2020-2030: Forecasts by Disease Type, Viral Diseases, Bacterial Diseases, Type of Vaccines, Distribution Channel, Age Group, Region, Competitive Landscape, COVID-19 Impact Analysis, Profiles of Leading Companies

出版日期: | 出版商: Visiongain Ltd | 英文 602 Pages | 商品交期: 最快1-2個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

本報告調查了全球疫苗銷售市場,包括市場規模,預測,機會,增長和抑制因素,疾病類型,病毒性疾病,疫苗類型,細菌性疾病,分銷渠道,年齡段和它提供諸如區域市場分析,競爭狀況以及主要公司的概況之類的信息。

目錄

第1章報告概述

第2章執行摘要

  • 對主導市場的細菌類型的需求不斷增加
  • 按年齡段分析
  • 通過分銷渠道分析
  • 區域市場洞察

第3章疫苗行業概述

  • 行業定義
  • 免疫系統和疫苗
  • 疫苗如何起作用
  • 免疫類型
    • 獲得的免疫力
    • 被動免疫
    • 接種疫苗的好處
  • 疫苗的歷史
  • 大流行的快速製造
    • 疫苗製造方法類型

第4章市場動態

  • 在COVID-19大流行中開發和分發疫苗
  • 生長因子
    • 兒童基金會,衛生組織和泛美衛生組織增加疫苗供應以支持疫苗接種過程
    • 研發支持的強勁供應
    • 競爭渠道將在預測期內擴大市場銷售
    • 快速製造等技術進步
    • 全球範圍內的疫苗接種增加
    • 政府對疫苗開發的支持
  • 抑製器
    • 與疫苗接種相關的高成本限制了採用
    • 低收入國家缺乏認識
    • 疫苗價格高
    • 對相關風險因素的擔憂日益增加
    • 疫苗供應不足
  • 全球市場的增長機會
    • RNA疫苗接種
    • 增加的抗生素耐藥性
    • 現狀
    • 開發和推出新疫苗
    • 加大研發力度
    • 新興市場需求增加
    • 政府提高免疫力的舉措
    • 全球疫苗和疫苗接種聯盟(GAVI)
    • 改善獲得可持續免疫服務的機會
    • 需求不均
    • 供應限制
    • 融資趨勢
    • 保護經濟勞動力
  • SWOT分析
  • 步驟分析

第5章COVID-19影響分析

  • COVID-19的研究與開發

第6章全球疫苗銷售市場展望

  • 市場概況
  • 市場概況
  • 基於數量的市場
  • 按疾病類型
  • 病毒性疾病
  • 按疫苗類型
    • 保留重組/綴合物/亞基片段的主要份額
    • 滅活□□疫苗
    • 類毒素疫苗
    • 亞單位疫苗
    • 結合疫苗
    • 重組載體疫苗
    • DNA疫苗
    • RNA疫苗
    • 佐劑和賦形劑
    • 病原體成分
    • 顆粒佐劑
    • 其他/組合疫苗
  • 細菌性疾病
  • 通過分銷渠道
  • 按年齡段
    • 小兒疫苗
    • 兒科疫苗的趨勢
    • 產前疫苗

第7章北美市場展望

  • 市場概況
  • 基於數量的市場
  • 按國家/地區分類:市場細分
  • 美國
  • 加拿大
  • 按疾病類型
  • 病毒性疾病
  • 按疫苗類型
  • 細菌性疾病
  • 通過分銷渠道
  • 按年齡段

第8章歐洲市場展望

  • 市場概況
  • 基於數量的市場
  • 按國家/地區分類:市場細分
  • 俄羅斯
  • 德國
  • 英國
  • 法國
  • 意大利
  • 其他國家
  • 按疾病類型
  • 病毒性疾病
  • 按疫苗類型
  • 細菌性疾病
  • 通過分銷渠道
  • 按年齡段

第9章亞太市場展望

  • 市場概況
  • 基於數量的市場
  • 按國家/地區分類:市場細分
  • 中國
  • 日本
  • 印度
  • 韓國
  • 澳大利亞
  • 其他國家
  • 按疾病類型
  • 病毒性疾病
  • 按疫苗類型
  • 細菌性疾病
  • 通過分銷渠道
  • 按年齡段

第10章中東和非洲市場展望

  • 市場概況
  • 基於數量的市場
  • 按國家/地區分類:市場細分
  • 土耳其
  • 沙特阿拉伯
  • 南非
  • 伊朗
  • 阿拉伯聯合酋長國
  • 其他國家
  • 按疾病類型
  • 病毒性疾病
  • 按疫苗類型
  • 細菌性疾病
  • 通過分銷渠道
  • 按年齡段

第11章拉丁美洲市場展望

  • 市場概況
  • 基於數量的市場
  • 按國家/地區分類:市場細分
  • 巴西
  • 墨西哥
  • 尼日利亞
  • 其他國家
  • 按疾病類型
  • 病毒性疾病
  • 按疫苗類型
  • 細菌性疾病
  • 通過分銷渠道
  • 按年齡段

第12章研究與開發疫苗

  • 鄧氏疫苗調查
    • 疫苗開發狀況
    • 疫苗開發麵臨的挑戰
    • 世衛組織的活動
  • 瘧疾疫苗
    • 疫苗開發狀況
  • 開發HIV疫苗
  • 開發腦膜炎疫苗
  • 流感疫苗
    • 開發流感疫苗
    • 疫苗開發狀況
    • 疫苗開發麵臨的挑戰
  • 結核疫苗的研製
  • 狄卡病毒疫苗產品開發
    • 鹿疫苗開發的技術路線圖
  • A組鏈球菌
  • RSV疫苗的研發

第13章主要公司簡介

  • 最新技術和公司
  • 市場份額
  • Astra Zeneca
    • 業務概述
    • 企業財務狀況
    • 產品和服務提供
    • 最新趨勢
  • Johnson & Johnson
  • Bavarian Nordic
  • Merck & Co.
  • Takeda Pharmaceutical Company
  • Roche Holding AG
  • GlaxoSmithKline PLC (GSK)
  • Bayer Inc.
  • Eli Lilly and Company
  • Bristol-Myers Squibb
  • Pfizer Inc.
  • Emergent BioSolutions Inc.
  • Fresenius SE & Co KGaA
  • Sanofi
  • BiondVaxPharmaceuticals Ltd.

第14章 結論與建議

目錄
Product Code: PHA0809

Vaccine Sales Market our new study reveals trends, R&D progress, and predicted revenues

Where is the Vaccines market heading? If you are involved in this sector you must read this newly updated report. Visiongain's report shows you the potential revenues streams to 2030, assessing data, trends, opportunities and business prospects there.

Discover how to stay ahead

Our 602 pages report provides 400+ tables and charts/graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Vaccines Market. See how to exploit the opportunities.

Forecasts to 2030 and other analyses reveal the commercial prospects

  • In addition to revenue forecasting to 2030, our new study provides you with recent results, growth rates, and market shares.
  • You find original analyses, with business outlooks and developments.
  • Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints, and challenges), product profiles and commercial developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect your industry.

Report Scope

  • Disease Type
    • Viral Diseases
    • Bacterial Diseases
  • Viral Diseases
    • Hepatitis
    • Influenza
    • Human Papillomavirus
    • Measles/Mumps/Rubella
    • Rotavirus
    • Other Viral Diseases
  • Bacterial Disease
    • Pneumococcal Disease
    • Meningococcal Disease
    • Diphtheria/Tetanus/Pertussis
    • Other Bacterial Disease
  • Type Vaccines
    • Recombinant/Conjugate/Subunit
    • Inactivated
    • Live Attenuated
    • Toxoid
  • Distribution Channel
    • Hospital & Retail Pharmacies
    • Government Suppliers
    • Other Distribution Channel
  • Age Group
    • Paediatrics
    • Adults
    • Other Age Groups

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 5 regional and 19 leading national markets:

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
    • Australia
    • Rest of Asia Pacific
  • Middle East and Africa
    • Saudi Arabia
    • South Africa
    • Iran
    • UAE
    • Rest of Middle East and Africa
  • Latin America
    • Brazil
    • Mexico
    • Nigeria
    • Rest of Latin America

Table of Contents

1. Report Overview

  • 1.1 Why You Should Buy This Report
  • 1.2 How This Report Delivers
  • 1.3 Key Questions Answered by This Analytical Report Include:
  • 1.4 Who is This Report For?
  • 1.5 Methodology
    • 1.5.1 Primary Research
    • 1.5.2 Secondary Research
    • 1.5.3 Data Sources
  • 1.6 Market Evaluation & Forecasting Methodology
  • 1.7 COIVD-19 Impact Recovery Pattern Analysis
    • 1.7.1 V-Shaped Recovery
    • 1.7.2 U-Shaped Recovery
    • 1.7.3 W-Shaped Recovery
    • 1.7.4 L-Shaped Recovery
  • 1.8 Frequently Asked Questions (FAQ)
  • 1.9 Associated Visiongain Reports
  • 1.10 About Visiongain

2. Executive Summary

  • 2.1.1 Growing Demand for Bacterial Type to Dominate the Market
    • 2.1.1.1 Due to higher sales of pneumococcal, meningitis and DTP worldwide, the segment of bacterial diseases has a dominant market share
  • 2.1.2 By Age Group Analysis
  • 2.1.3 By Distribution Channel Analysis
  • 2.1.4 Regional Market Insight

3. Vaccine Industry Overview

  • 3.1 Industry Definitions
  • 3.2 Immune System and Vaccines
  • 3.3 How Vaccines Work
  • 3.4 Types of Immunity
    • 3.4.1 Active Immunity
    • 3.4.2 Passive Immunity
    • 3.4.3 Advantages of Vaccination
  • 3.5 History of Vaccines
  • 3.6 Rapid Manufacturing for Pandemics
    • 3.6.1 Types of Vaccine Manufacturing Methods

4. Market Dynamics

  • 4.1 Vaccine Development and Distribution Amid the COVID-19 Pandemic
  • 4.2 Market Growth Driving Factors
    • 4.2.1 Growing Vaccines Supply by UNICEF, WHO, PAHO to Aid Immunization Process
    • 4.2.2 Strong Supply Backed Up by Robust R&D to Drive the Market
    • 4.2.3 Competitive Pipeline to Expand the Market Value During the Forecast Period
    • 4.2.4 Technological Advancements such as Rapid Manufacturing and Others
    • 4.2.5 Rising Immunization Across the Globe
    • 4.2.6 Government Support for Vaccine Development
  • 4.3 Market Growth Restraining Factors
    • 4.3.1 High Cost Associated with Vaccine Dose to Limit Adoption
    • 4.3.2 Lack of Awareness in Low-Income Countries
    • 4.3.1 High Prices of Vaccines
    • 4.3.1 Rising Concerns of Associated Risk Factors
    • 4.3.2 Inadequate Vaccine Supply
  • 4.4 Growth Opportunities in the Global Market
    • 4.4.1 RNA Vaccination
    • 4.4.2 Rise of Antibiotic Resistance
    • 4.4.3 Current Situation
    • 4.4.4 Development and Launch of New Vaccines
    • 4.4.5 Increased R&D Efforts
    • 4.4.6 Increased Demand from Emerging Markets
    • 4.4.7 Government Initiatives for Increased Immunizations
    • 4.4.8 Global Alliance for Vaccines and Immunization (GAVI)
    • 4.4.9 Improving access to sustainable immunization services.
    • 4.4.10 Undulating Demand
    • 4.4.11 Supply Restraints
    • 4.4.12 Funding Trends
    • 4.4.13 Protecting the Workforce of an Economy
  • 4.5 SWOT Analysis of the World Human Vaccines Market
    • 4.5.1 Strengths
    • 4.5.2 Weaknesses
    • 4.5.3 Opportunities
    • 4.5.4 Threats
  • 4.6 STEP Analysis of the World Human Vaccines Industry and Market
    • 4.6.1 Social Factors
    • 4.6.2 Technological Forces
    • 4.6.3 Economic Factors
    • 4.6.4 Political Factors

5. COVID-19 Impact Analysis

  • 5.1 Research and Development on COVID-19

6. Global Vaccines Sales Market Outlook

  • 6.1 Market Overview
  • 6.2 Market in Terms of Value
    • 6.2.1 Market in Terms of Value (Normal Recovery)
    • 6.2.2 Market in Terms of Value (V-Shaped Recovery)
    • 6.2.3 Market in Terms of Value (W-Shaped Recovery)
    • 6.2.4 Market in Terms of Value (U-Shaped Recovery)
  • 6.3 Global Market Breakdown by Region
      • 6.3.1.1 North America is expected to dominate the global market during the forecast period
    • 6.3.1 Market in Terms of Value (Normal Recovery)
    • 6.3.2 Market in Terms of Value (V-Shaped Recovery)
    • 6.3.3 Market in Terms of Value (W-Shaped Recovery)
    • 6.3.4 Market in Terms of Value (U-Shaped Recovery)
    • 6.3.5 Market in Terms of Value (L-Shaped Recovery)
  • 6.4 Global Market Breakdown by Disease Type
      • 6.4.1.1 Bacterial Diseases the segment held the significant share in the overall market and is expected to offer an opportunity throughout the forecast period
    • 6.4.1 Market in Terms of Value (Normal Recovery)
    • 6.4.2 Market in Terms of Value (V-Shaped Recovery)
    • 6.4.3 Market in Terms of Value (W-Shaped Recovery)
    • 6.4.4 Market in Terms of Value (U-Shaped Recovery)
    • 6.4.5 Market in Terms of Value (L-Shaped Recovery)
  • 6.5 Global Market Breakdown by Viral Diseases
      • 6.5.1.1 Hepatitis Segment is expected to have the highest CAGR during forecast period.
    • 6.5.1 Human Diseases
    • 6.5.1 Market in Terms of Value (Normal Recovery)
    • 6.5.2 Market in Terms of Value (V-Shaped Recovery)
    • 6.5.3 Market in Terms of Value (W-Shaped Recovery)
    • 6.5.4 Market in Terms of Value (U-Shaped Recovery)
    • 6.5.5 Market in Terms of Value (L-Shaped Recovery)
  • 6.6 Global Market Breakdown by Vaccine Type
    • 6.6.1 Recombinant/Conjugate/Subunit the segment held the significant share
    • 6.6.2 Inactivated (Killed) Vaccines
    • 6.6.3 Toxoid Vaccines
    • 6.6.4 Subunit Vaccines
    • 6.6.5 Conjugate Vaccines
    • 6.6.6 Recombinant Vector Vaccines
    • 6.6.7 DNA Vaccines
    • 6.6.8 RNA Vaccines
    • 6.6.9 Adjuvants and Excipients
    • 6.6.10 Pathogen Components
    • 6.6.11 Particulate Adjuvants
    • 6.6.12 Other/Combination Vaccines
    • 6.6.13 Market in Terms of Value (Normal Recovery)
    • 6.6.14 Market in Terms of Value (V-Shaped Recovery)
    • 6.6.15 Market in Terms of Value (W-Shaped Recovery)
    • 6.6.16 Market in Terms of Value (U-Shaped Recovery)
    • 6.6.17 Market in Terms of Value (L-Shaped Recovery)
  • 6.7 Global Market Breakdown by Bacterial Disease
      • 6.7.1.1 Pneumococcal Disease is expected to offer an opportunity throughout the forecast period
    • 6.7.1 Market in Terms of Value (Normal Recovery)
    • 6.7.2 Market in Terms of Value (V-Shaped Recovery)
    • 6.7.3 Market in Terms of Value (W-Shaped Recovery)
    • 6.7.4 Market in Terms of Value (U-Shaped Recovery)
    • 6.7.5 Market in Terms of Value (L-Shaped Recovery)
  • 6.8 Global Market Breakdown by Distribution Channel
      • 6.8.1.1 A dominant share of the income is anticipated for hospital and retail pharmacies
    • 6.8.1 Market in Terms of Value (Normal Recovery)
    • 6.8.2 Market in Terms of Value (V-Shaped Recovery)
    • 6.8.3 Market in Terms of Value (W-Shaped Recovery)
    • 6.8.4 Market in Terms of Value (U-Shaped Recovery)
    • 6.8.5 Market in Terms of Value (L-Shaped Recovery)
  • 6.9 Global Market Breakdown by Age Group
    • 6.9.1 Pediatric Vaccines
    • 6.9.2 Paediatric Vaccine Trends
    • 6.9.3 Prenatal Vaccines
    • 6.9.4 Market in Terms of Value (Normal Recovery)
    • 6.9.5 Market in Terms of Value (V-Shaped Recovery)
    • 6.9.6 Market in Terms of Value (W-Shaped Recovery)
    • 6.9.7 Market in Terms of Value (U-Shaped Recovery)
    • 6.9.8 Market in Terms of Value (L-Shaped Recovery)

7. North America Vaccines Sales Market Outlook

    • 7.1.1 Growth attributed to vaccination compulsion or mandate
  • 7.1 North America Market Overview
  • 7.2 North America Market in Terms of Value
    • 7.2.1 Market in Terms of Value (Normal Recovery)
    • 7.2.2 Market in Terms of Value (V-Shaped Recovery)
    • 7.2.3 Market in Terms of Value (W-Shaped Recovery)
    • 7.2.4 Market in Terms of Value (U-Shaped Recovery)
    • 7.2.5 Market in Terms of Value (L-Shaped Recovery)
  • 7.3 North America Market Breakdown by Country
    • 7.3.1 Market in Terms of Value (Normal Recovery)
    • 7.3.2 Market in Terms of Value (V-Shaped Recovery)
    • 7.3.3 Market in Terms of Value (W-Shaped Recovery)
    • 7.3.4 Market in Terms of Value (U-Shaped Recovery)
    • 7.3.5 Market in Terms of Value (L-Shaped Recovery)
  • 7.4 U.S. Vaccine Sales Market Outlook
      • 7.4.1.1 The country is expected to offer an opportunity throughout the forecast period
    • 7.4.1 Market in Terms of Value (Normal Recovery)
    • 7.4.2 Market in Terms of Value (V-Shaped Recovery)
    • 7.4.3 Market in Terms of Value (W-Shaped Recovery)
    • 7.4.4 Market in Terms of Value (U-Shaped Recovery)
    • 7.4.5 Market in Terms of Value (L-Shaped Recovery)
  • 7.5 Canada Vaccine Sales Market Outlook
      • 7.5.1.1 Market is supported by consistent and sustained funding of immunization programs
    • 7.5.1 Market in Terms of Value (Normal Recovery)
    • 7.5.2 Market in Terms of Value (V-Shaped Recovery)
    • 7.5.3 Market in Terms of Value (W-Shaped Recovery)
    • 7.5.4 Market in Terms of Value (U-Shaped Recovery)
    • 7.5.5 Market in Terms of Value (L-Shaped Recovery)
  • 7.6 North America Market Breakdown by Disease Type
    • 7.6.1 Market in Terms of Value (Normal Recovery)
    • 7.6.2 Market in Terms of Value (V-Shaped Recovery)
    • 7.6.3 Market in Terms of Value (W-Shaped Recovery)
    • 7.6.4 Market in Terms of Value (U-Shaped Recovery)
    • 7.6.5 Market in Terms of Value (L-Shaped Recovery)
  • 7.7 North America Market Breakdown by Viral Diseases
    • 7.7.1 Market in Terms of Value (Normal Recovery)
    • 7.7.2 Market in Terms of Value (V-Shaped Recovery)
    • 7.7.3 Market in Terms of Value (W-Shaped Recovery)
    • 7.7.4 Market in Terms of Value (U-Shaped Recovery)
    • 7.7.5 Market in Terms of Value (L-Shaped Recovery)
  • 7.8 North America Market Breakdown by Vaccine Type
    • 7.8.1 Market in Terms of Value (Normal Recovery)
    • 7.8.2 Market in Terms of Value (V-Shaped Recovery)
    • 7.8.3 Market in Terms of Value (W-Shaped Recovery)
    • 7.8.4 Market in Terms of Value (U-Shaped Recovery)
    • 7.8.5 Market in Terms of Value (L-Shaped Recovery)
  • 7.9 North America Market Breakdown by Bacterial Disease
    • 7.9.1 Market in Terms of Value (Normal Recovery)
    • 7.9.2 Market in Terms of Value (V-Shaped Recovery)
    • 7.9.3 Market in Terms of Value (W-Shaped Recovery)
    • 7.9.4 Market in Terms of Value (U-Shaped Recovery)
    • 7.9.5 Market in Terms of Value (L-Shaped Recovery)
  • 7.10 North America Market Breakdown by Distribution Channel
    • 7.10.1 Market in Terms of Value (Normal Recovery)
    • 7.10.2 Market in Terms of Value (V-Shaped Recovery)
    • 7.10.3 Market in Terms of Value (W-Shaped Recovery)
    • 7.10.4 Market in Terms of Value (U-Shaped Recovery)
    • 7.10.5 Market in Terms of Value (L-Shaped Recovery)
  • 7.11 North America Market Breakdown by Age Group
    • 7.11.1 Market in Terms of Value (Normal Recovery)
    • 7.11.2 Market in Terms of Value (V-Shaped Recovery)
    • 7.11.3 Market in Terms of Value (W-Shaped Recovery)
    • 7.11.4 Market in Terms of Value (U-Shaped Recovery)
    • 7.11.5 Market in Terms of Value (L-Shaped Recovery)

8. Europe Vaccines Sales Market Outlook

  • 8.1 Europe Market Overview
    • 8.1.1 A considerable growth in the vaccine market is expected in the European region.
  • 8.2 Europe Market in Terms of Value
    • 8.2.1 Market in Terms of Value (Normal Recovery)
    • 8.2.2 Market in Terms of Value (V-Shaped Recovery)
    • 8.2.3 Market in Terms of Value (W-Shaped Recovery)
    • 8.2.4 Market in Terms of Value (U-Shaped Recovery)
    • 8.2.5 Market in Terms of Value (L-Shaped Recovery)
  • 8.3 Europe Market Breakdown by Country
    • 8.3.1 Market in Terms of Value (Normal Recovery)
    • 8.3.2 Market in Terms of Value (V-Shaped Recovery)
    • 8.3.3 Market in Terms of Value (W-Shaped Recovery)
    • 8.3.4 Market in Terms of Value (U-Shaped Recovery)
    • 8.3.5 Market in Terms of Value (L-Shaped Recovery)
  • 8.4 Russia Vaccine Sales Market Outlook
      • 8.4.1.1 The Russian Federation has purchased over 90% of the total supply of the vaccines in the market
    • 8.4.1 Market in Terms of Value (Normal Recovery)
    • 8.4.2 Market in Terms of Value (V-Shaped Recovery)
    • 8.4.3 Market in Terms of Value (W-Shaped Recovery)
    • 8.4.4 Market in Terms of Value (U-Shaped Recovery)
    • 8.4.5 Market in Terms of Value (L-Shaped Recovery)
  • 8.5 Germany Vaccine Sales Market Outlook
    • 8.5.1.1 Germany is expected to offer an opportunity throughout the forecast period.
    • 8.5.1 Market in Terms of Value (Normal Recovery)
    • 8.5.2 Market in Terms of Value (V-Shaped Recovery)
    • 8.5.3 Market in Terms of Value (W-Shaped Recovery)
    • 8.5.4 Market in Terms of Value (U-Shaped Recovery)
    • 8.5.5 Market in Terms of Value (L-Shaped Recovery)
  • 8.6 UK Vaccine Sales Market Outlook
      • 8.6.1.1 The U.K. is one of the major contributors to the vaccine market
    • 8.6.1 Market in Terms of Value (Normal Recovery)
    • 8.6.1 Market in Terms of Value (V-Shaped Recovery)
    • 8.6.2 Market in Terms of Value (W-Shaped Recovery)
    • 8.6.3 Market in Terms of Value (U-Shaped Recovery)
    • 8.6.4 Market in Terms of Value (L-Shaped Recovery)
  • 8.7 France Vaccine Sales Market Outlook
      • 8.7.1.1 France is one of the major countries to produce vaccines
    • 8.7.1 Market in Terms of Value (Normal Recovery)
    • 8.7.2 Market in Terms of Value (V-Shaped Recovery)
    • 8.7.3 Market in Terms of Value (W-Shaped Recovery)
    • 8.7.4 Market in Terms of Value (U-Shaped Recovery)
    • 8.7.5 Market in Terms of Value (L-Shaped Recovery)
  • 8.8 Italy Vaccine Sales Market Outlook
      • 8.8.1.1 Italy is the fourth largest market for human vaccines within Europe
    • 8.8.1 Market in Terms of Value (Normal Recovery)
    • 8.8.2 Market in Terms of Value (V-Shaped Recovery)
    • 8.8.3 Market in Terms of Value (W-Shaped Recovery)
    • 8.8.4 Market in Terms of Value (U-Shaped Recovery)
    • 8.8.5 Market in Terms of Value (L-Shaped Recovery)
  • 8.9 Rest of Europe Vaccine Sales Market Outlook
    • 8.9.1 Market in Terms of Value (Normal Recovery)
    • 8.9.2 Market in Terms of Value (V-Shaped Recovery)
    • 8.9.3 Market in Terms of Value (W-Shaped Recovery)
    • 8.9.4 Market in Terms of Value (U-Shaped Recovery)
    • 8.9.5 Market in Terms of Value (L-Shaped Recovery)
  • 8.10 Europe Market Breakdown by Disease Type
    • 8.10.1 Market in Terms of Value (Normal Recovery)
    • 8.10.2 Market in Terms of Value (V-Shaped Recovery)
    • 8.10.3 Market in Terms of Value (W-Shaped Recovery)
    • 8.10.4 Market in Terms of Value (U-Shaped Recovery)
    • 8.10.5 Market in Terms of Value (L-Shaped Recovery)
  • 8.11 Europe Market Breakdown by Viral Disease
    • 8.11.1 Market in Terms of Value (Normal Recovery)
    • 8.11.2 Market in Terms of Value (V-Shaped Recovery)
    • 8.11.3 Market in Terms of Value (W-Shaped Recovery)
    • 8.11.4 Market in Terms of Value (U-Shaped Recovery)
    • 8.11.5 Market in Terms of Value (L-Shaped Recovery)
  • 8.12 Europe Market Breakdown by Vaccine Type
    • 8.12.1 Market in Terms of Value (Normal Recovery)
    • 8.12.2 Market in Terms of Value (V-Shaped Recovery)
    • 8.12.3 Market in Terms of Value (W-Shaped Recovery)
    • 8.12.4 Market in Terms of Value (U-Shaped Recovery)
    • 8.12.5 Market in Terms of Value (L-Shaped Recovery)
  • 8.13 Europe Market Breakdown by Bacterial Disease
    • 8.13.1 Market in Terms of Value (Normal Recovery)
    • 8.13.2 Market in Terms of Value (V-Shaped Recovery)
    • 8.13.3 Market in Terms of Value (W-Shaped Recovery)
    • 8.13.4 Market in Terms of Value (U-Shaped Recovery)
    • 8.13.5 Market in Terms of Value (L-Shaped Recovery)
  • 8.14 Europe Market Breakdown by Distribution Channel
    • 8.14.1 Market in Terms of Value (Normal Recovery)
    • 8.14.2 Market in Terms of Value (V-Shaped Recovery)
    • 8.14.3 Market in Terms of Value (W-Shaped Recovery)
    • 8.14.4 Market in Terms of Value (U-Shaped Recovery)
    • 8.14.5 Market in Terms of Value (L-Shaped Recovery)
  • 8.15 Europe Market Breakdown by Age Group
    • 8.15.1 Market in Terms of Value (Normal Recovery)
    • 8.15.2 Market in Terms of Value (V-Shaped Recovery)
    • 8.15.3 Market in Terms of Value (W-Shaped Recovery)
    • 8.15.4 Market in Terms of Value (U-Shaped Recovery)
    • 8.15.5 Market in Terms of Value (L-Shaped Recovery)

9. Asia-Pacific Vaccines Sales Market Outlook

  • 9.1 Asia-Pacific Market Overview
  • 9.2 Asia-Pacific Market in Terms of Value
    • 9.2.1 Market in Terms of Value (Normal Recovery)
    • 9.2.2 Market in Terms of Value (V-Shaped Recovery)
    • 9.2.3 Market in Terms of Value (W-Shaped Recovery)
    • 9.2.4 Market in Terms of Value (U-Shaped Recovery)
    • 9.2.5 Market in Terms of Value (L-Shaped Recovery)
  • 9.3 Asia-Pacific Market Breakdown by Country
    • 9.3.1 Market in Terms of Value (Normal Recovery)
    • 9.3.2 Market in Terms of Value (V-Shaped Recovery)
    • 9.3.3 Market in Terms of Value (W-Shaped Recovery)
    • 9.3.4 Market in Terms of Value (U-Shaped Recovery)
    • 9.3.5 Market in Terms of Value (L-Shaped Recovery)
  • 9.4 China Vaccine Sales Market Outlook
      • 9.4.1.1 Growth prospects remain strong in the country
    • 9.4.1 Market in Terms of Value (Normal Recovery)
    • 9.4.2 Market in Terms of Value (V-Shaped Recovery)
    • 9.4.3 Market in Terms of Value (W-Shaped Recovery)
    • 9.4.4 Market in Terms of Value (U-Shaped Recovery)
    • 9.4.5 Market in Terms of Value (L-Shaped Recovery)
  • 9.5 Japan Vaccine Sales Market Outlook
      • 9.5.1.1 Japan is expected to offer an opportunity throughout the forecast period
    • 9.5.1 Market in Terms of Value (Normal Recovery)
    • 9.5.2 Market in Terms of Value (V-Shaped Recovery)
    • 9.5.3 Market in Terms of Value (W-Shaped Recovery)
    • 9.5.4 Market in Terms of Value (U-Shaped Recovery)
    • 9.5.5 Market in Terms of Value (L-Shaped Recovery)
  • 9.6 India Vaccine Sales Market Outlook
      • 9.6.1.1 The prevalence of the diseases has been quite high in India, which is driving the market growth
    • 9.6.1 Market in Terms of Value (Normal Recovery)
    • 9.6.2 Market in Terms of Value (V-Shaped Recovery)
    • 9.6.3 Market in Terms of Value (W-Shaped Recovery)
    • 9.6.4 Market in Terms of Value (U-Shaped Recovery)
    • 9.6.5 Market in Terms of Value (L-Shaped Recovery)
  • 9.7 South Korea Vaccine Sales Market Outlook
      • 9.7.1.1 Korea has been importing all demand for this vaccine due to a lack of homegrown technology to develop a vaccine locally
    • 9.7.1 Market in Terms of Value (Normal Recovery)
    • 9.7.2 Market in Terms of Value (V-Shaped Recovery)
    • 9.7.3 Market in Terms of Value (W-Shaped Recovery)
    • 9.7.4 Market in Terms of Value (U-Shaped Recovery)
    • 9.7.5 Market in Terms of Value (L-Shaped Recovery)
  • 9.8 Australia Vaccine Sales Market Outlook
      • 9.8.1.1 Australia is on track for a record number of flu vaccinations
    • 9.8.1 Market in Terms of Value (Normal Recovery)
    • 9.8.2 Market in Terms of Value (V-Shaped Recovery)
    • 9.8.3 Market in Terms of Value (W-Shaped Recovery)
    • 9.8.4 Market in Terms of Value (U-Shaped Recovery)
    • 9.8.5 Market in Terms of Value (L-Shaped Recovery)
  • 9.9 Rest of Asia-Pacific Vaccine Sales Market Outlook
    • 9.9.1 Market in Terms of Value (Normal Recovery)
    • 9.9.2 Market in Terms of Value (V-Shaped Recovery)
    • 9.9.3 Market in Terms of Value (W-Shaped Recovery)
    • 9.9.4 Market in Terms of Value (U-Shaped Recovery)
    • 9.9.5 Market in Terms of Value (L-Shaped Recovery)
  • 9.10 Asia-Pacific Market Breakdown by Disease Type
    • 9.10.1 Market in Terms of Value (Normal Recovery)
    • 9.10.2 Market in Terms of Value (V-Shaped Recovery)
    • 9.10.3 Market in Terms of Value (W-Shaped Recovery)
    • 9.10.4 Market in Terms of Value (U-Shaped Recovery)
    • 9.10.5 Market in Terms of Value (L-Shaped Recovery)
  • 9.11 Asia-Pacific Market Breakdown by Viral Diseases
    • 9.11.1 Market in Terms of Value (Normal Recovery)
    • 9.11.2 Market in Terms of Value (V-Shaped Recovery)
    • 9.11.3 Market in Terms of Value (W-Shaped Recovery)
    • 9.11.4 Market in Terms of Value (U-Shaped Recovery)
    • 9.11.5 Market in Terms of Value (L-Shaped Recovery)
  • 9.12 Asia-Pacific Market Breakdown by Vaccine Type
    • 9.12.1 Market in Terms of Value (Normal Recovery)
    • 9.12.2 Market in Terms of Value (V-Shaped Recovery)
    • 9.12.3 Market in Terms of Value (W-Shaped Recovery)
    • 9.12.4 Market in Terms of Value (U-Shaped Recovery)
    • 9.12.5 Market in Terms of Value (L-Shaped Recovery)
  • 9.13 Asia-Pacific Market Breakdown by Bacterial Disease
    • 9.13.1 Market in Terms of Value (Normal Recovery)
    • 9.13.2 Market in Terms of Value (V-Shaped Recovery)
    • 9.13.3 Market in Terms of Value (W-Shaped Recovery)
    • 9.13.4 Market in Terms of Value (U-Shaped Recovery)
    • 9.13.5 Market in Terms of Value (L-Shaped Recovery)
  • 9.14 Asia-Pacific Market Breakdown by Distribution Channel
    • 9.14.1 Market in Terms of Value (Normal Recovery)
    • 9.14.2 Market in Terms of Value (V-Shaped Recovery)
    • 9.14.3 Market in Terms of Value (W-Shaped Recovery)
    • 9.14.4 Market in Terms of Value (U-Shaped Recovery)
    • 9.14.5 Market in Terms of Value (L-Shaped Recovery)
  • 9.15 Asia-Pacific Market Breakdown by Age Group
    • 9.15.1 Market in Terms of Value (Normal Recovery)
    • 9.15.2 Market in Terms of Value (V-Shaped Recovery)
    • 9.15.3 Market in Terms of Value (W-Shaped Recovery)
    • 9.15.4 Market in Terms of Value (U-Shaped Recovery)
    • 9.15.5 Market in Terms of Value (L-Shaped Recovery)

10. Middle East & Africa Vaccines Sales Market Outlook

  • 10.1 Middle East & Africa Market Overview
  • 10.2 Middle East & Africa Market in Terms of Value
    • 10.2.1 Market in Terms of Value (Normal Recovery)
    • 10.2.2 Market in Terms of Value (V-Shaped Recovery)
    • 10.2.3 Market in Terms of Value (W-Shaped Recovery)
    • 10.2.4 Market in Terms of Value (U-Shaped Recovery)
    • 10.2.5 Market in Terms of Value (L-Shaped Recovery)
  • 10.3 Middle East & Africa Market Breakdown by Country
    • 10.3.1 Market in Terms of Value (Normal Recovery)
    • 10.3.2 Market in Terms of Value (V-Shaped Recovery)
    • 10.3.3 Market in Terms of Value (W-Shaped Recovery)
    • 10.3.4 Market in Terms of Value (U-Shaped Recovery)
    • 10.3.5 Market in Terms of Value (L-Shaped Recovery)
  • 10.4 Turkey Vaccine Sales Market Outlook
    • 10.4.1 Market in Terms of Value (Normal Recovery)
    • 10.4.2 Market in Terms of Value (V-Shaped Recovery)
    • 10.4.3 Market in Terms of Value (W-Shaped Recovery)
    • 10.4.4 Market in Terms of Value (U-Shaped Recovery)
    • 10.4.5 Market in Terms of Value (L-Shaped Recovery)
  • 10.5 Saudi Arabia Vaccine Sales Market Outlook
      • 10.5.1.1 Healthcare is the third largest beneficiary behind education and military
    • 10.5.1 Market in Terms of Value (Normal Recovery)
    • 10.5.2 Market in Terms of Value (V-Shaped Recovery)
    • 10.5.3 Market in Terms of Value (W-Shaped Recovery)
    • 10.5.4 Market in Terms of Value (U-Shaped Recovery)
    • 10.5.5 Market in Terms of Value (L-Shaped Recovery)
  • 10.6 South Africa Vaccine Sales Market Outlook
      • 10.6.1.1 Pneumonia vaccine alone used up 40% of South Africa's total budget for vaccines
    • 10.6.1 Market in Terms of Value (Normal Recovery)
    • 10.6.2 Market in Terms of Value (V-Shaped Recovery)
    • 10.6.3 Market in Terms of Value (W-Shaped Recovery)
    • 10.6.4 Market in Terms of Value (U-Shaped Recovery)
    • 10.6.5 Market in Terms of Value (L-Shaped Recovery)
  • 10.7 Iran Vaccine Sales Market Outlook
      • 10.7.1.1. Iran's vaccine industry, has a long history and international reputation
    • 10.7.1 Market in Terms of Value (Normal Recovery)
    • 10.7.2 Market in Terms of Value (V-Shaped Recovery)
    • 10.7.3 Market in Terms of Value (W-Shaped Recovery)
    • 10.7.4 Market in Terms of Value (U-Shaped Recovery)
    • 10.7.5 Market in Terms of Value (L-Shaped Recovery)
  • 10.8 UAE Vaccine Sales Market Outlook
    • 10.8.1 Market in Terms of Value (Normal Recovery)
    • 10.8.2 Market in Terms of Value (V-Shaped Recovery)
    • 10.8.3 Market in Terms of Value (W-Shaped Recovery)
    • 10.8.4 Market in Terms of Value (U-Shaped Recovery)
    • 10.8.5 Market in Terms of Value (L-Shaped Recovery)
  • 10.9 Rest of Middle East & Africa Vaccine Sales Market Outlook
    • 10.9.1 Market in Terms of Value (Normal Recovery)
    • 10.9.2 Market in Terms of Value (V-Shaped Recovery)
    • 10.9.3 Market in Terms of Value (W-Shaped Recovery)
    • 10.9.4 Market in Terms of Value (U-Shaped Recovery)
    • 10.9.5 Market in Terms of Value (L-Shaped Recovery)
  • 10.10 Middle East & Africa Market Breakdown by Disease Type
    • 10.10.1 Market in Terms of Value (Normal Recovery)
    • 10.10.2 Market in Terms of Value (V-Shaped Recovery)
    • 10.10.3 Market in Terms of Value (W-Shaped Recovery)
    • 10.10.4 Market in Terms of Value (U-Shaped Recovery)
    • 10.10.5 Market in Terms of Value (L-Shaped Recovery)
  • 10.11 Middle East & Africa Market Breakdown by Viral Diseases
    • 10.11.1 Market in Terms of Value (Normal Recovery)
    • 10.11.2 Market in Terms of Value (V-Shaped Recovery)
    • 10.11.3 Market in Terms of Value (W-Shaped Recovery)
    • 10.11.4 Market in Terms of Value (U-Shaped Recovery)
    • 10.11.5 Market in Terms of Value (L-Shaped Recovery)
  • 10.12 Middle East & Africa Market Breakdown by Vaccine Type
    • 10.12.1 Market in Terms of Value (Normal Recovery)
    • 10.12.2 Market in Terms of Value (V-Shaped Recovery)
    • 10.12.3 Market in Terms of Value (W-Shaped Recovery)
    • 10.12.4 Market in Terms of Value (U-Shaped Recovery)
    • 10.12.5 Market in Terms of Value (L-Shaped Recovery)
  • 10.13 Middle East & Africa Market Breakdown by Bacterial Disease
    • 10.13.1 Market in Terms of Value (Normal Recovery)
    • 10.13.2 Market in Terms of Value (V-Shaped Recovery)
    • 10.13.3 Market in Terms of Value (W-Shaped Recovery)
    • 10.13.4 Market in Terms of Value (U-Shaped Recovery)
    • 10.13.5 Market in Terms of Value (L-Shaped Recovery)
  • 10.14 Middle East & Africa Market Breakdown by Distribution Channel
    • 10.14.1 Market in Terms of Value (Normal Recovery)
    • 10.14.2 Market in Terms of Value (V-Shaped Recovery)
    • 10.14.3 Market in Terms of Value (W-Shaped Recovery)
    • 10.14.4 Market in Terms of Value (U-Shaped Recovery)
    • 10.14.5 Market in Terms of Value (L-Shaped Recovery)
  • 10.15 Middle East & Africa Market Breakdown by Age Group
    • 10.15.1 Market in Terms of Value (Normal Recovery)
    • 10.15.2 Market in Terms of Value (V-Shaped Recovery)
    • 10.15.3 Market in Terms of Value (W-Shaped Recovery)
    • 10.15.4 Market in Terms of Value (U-Shaped Recovery)
    • 10.15.5 Market in Terms of Value (L-Shaped Recovery)

11. Latin America Vaccines Sales Market Outlook

  • 11.1 Latin America Market Overview
  • 11.2 Latin America Market in Terms of Value
    • 11.2.1 Market in Terms of Value (Normal Recovery)
    • 11.2.2 Market in Terms of Value (V-Shaped Recovery)
    • 11.2.3 Market in Terms of Value (W-Shaped Recovery)
    • 11.2.4 Market in Terms of Value (U-Shaped Recovery)
    • 11.2.5 Market in Terms of Value (L-Shaped Recovery)
  • 11.3 Latin America Market Breakdown by Country
    • 11.3.1 Market in Terms of Value (Normal Recovery)
    • 11.3.2 Market in Terms of Value (V-Shaped Recovery)
    • 11.3.3 Market in Terms of Value (W-Shaped Recovery)
    • 11.3.4 Market in Terms of Value (U-Shaped Recovery)
    • 11.3.5 Market in Terms of Value (L-Shaped Recovery)
  • 11.4 Brazil Vaccine Sales Market Outlook
      • 11.4.1.1 The Brazilian human vaccines market is the largest in Latin America
    • 11.4.1 Market in Terms of Value (Normal Recovery)
    • 11.4.2 Market in Terms of Value (V-Shaped Recovery)
    • 11.4.3 Market in Terms of Value (W-Shaped Recovery)
    • 11.4.4 Market in Terms of Value (U-Shaped Recovery)
    • 11.4.5 Market in Terms of Value (L-Shaped Recovery)
  • 11.5 Mexico Vaccine Sales Market Outlook
    • 11.5.1 Market in Terms of Value (Normal Recovery)
    • 11.5.2 Market in Terms of Value (V-Shaped Recovery)
    • 11.5.3 Market in Terms of Value (W-Shaped Recovery)
    • 11.5.4 Market in Terms of Value (U-Shaped Recovery)
    • 11.5.5 Market in Terms of Value (L-Shaped Recovery)
  • 11.6 Nigeria Vaccine Sales Market Outlook
      • 11.6.1.1 The market is expected to grow at a decent growth rate during forecast period
    • 11.6.1 Market in Terms of Value (Normal Recovery)
    • 11.6.2 Market in Terms of Value (V-Shaped Recovery)
    • 11.6.3 Market in Terms of Value (W-Shaped Recovery)
    • 11.6.4 Market in Terms of Value (U-Shaped Recovery)
    • 11.6.5 Market in Terms of Value (L-Shaped Recovery)
  • 11.7 Rest of Latin America Vaccine Sales Market Outlook
    • 11.7.1 Market in Terms of Value (Normal Recovery)
    • 11.7.2 Market in Terms of Value (V-Shaped Recovery)
    • 11.7.3 Market in Terms of Value (W-Shaped Recovery)
    • 11.7.4 Market in Terms of Value (U-Shaped Recovery)
    • 11.7.5 Market in Terms of Value (L-Shaped Recovery)
  • 11.8 Latin America Market Breakdown by Disease Type
    • 11.8.1 Market in Terms of Value (Normal Recovery)
    • 11.8.2 Market in Terms of Value (V-Shaped Recovery)
    • 11.8.3 Market in Terms of Value (W-Shaped Recovery)
    • 11.8.4 Market in Terms of Value (U-Shaped Recovery)
    • 11.8.5 Market in Terms of Value (L-Shaped Recovery)
  • 11.9 Latin America Market Breakdown by Viral Diseases
    • 11.9.1 Market in Terms of Value (Normal Recovery)
    • 11.9.2 Market in Terms of Value (V-Shaped Recovery)
    • 11.9.3 Market in Terms of Value (W-Shaped Recovery)
    • 11.9.4 Market in Terms of Value (U-Shaped Recovery)
    • 11.9.5 Market in Terms of Value (L-Shaped Recovery)
  • 11.10 Latin America Market Breakdown by Vaccine Type
    • 11.10.1 Market in Terms of Value (Normal Recovery)
    • 11.10.2 Market in Terms of Value (V-Shaped Recovery)
    • 11.10.3 Market in Terms of Value (W-Shaped Recovery)
    • 11.10.4 Market in Terms of Value (U-Shaped Recovery)
    • 11.10.5 Market in Terms of Value (L-Shaped Recovery)
  • 11.11 Latin America Market Breakdown by Bacterial Diseases
    • 11.11.1 Market in Terms of Value (Normal Recovery)
    • 11.11.2 Market in Terms of Value (V-Shaped Recovery)
    • 11.11.3 Market in Terms of Value (W-Shaped Recovery)
    • 11.11.4 Market in Terms of Value (U-Shaped Recovery)
    • 11.11.5 Market in Terms of Value (L-Shaped Recovery)
  • 11.12 Latin America Market Breakdown by Distribution Channel
    • 11.12.1 Market in Terms of Value (Normal Recovery)
    • 11.12.2 Market in Terms of Value (V-Shaped Recovery)
    • 11.12.3 Market in Terms of Value (W-Shaped Recovery)
    • 11.12.4 Market in Terms of Value (U-Shaped Recovery)
    • 11.12.5 Market in Terms of Value (L-Shaped Recovery)
  • 11.13 Latin America Market Breakdown by Age Group
    • 11.13.1 Market in Terms of Value (Normal Recovery)
    • 11.13.2 Market in Terms of Value (V-Shaped Recovery)
    • 11.13.3 Market in Terms of Value (W-Shaped Recovery)
    • 11.13.4 Market in Terms of Value (U-Shaped Recovery)
    • 11.13.5 Market in Terms of Value (L-Shaped Recovery)

12. Vaccines Under Research & Development

  • 12.1 Dengue Vaccine Research
    • 12.1.1 Status of vaccine development
    • 12.1.2 Challenges to Vaccine Development
    • 12.1.3 WHO activities
  • 12.2 Malaria vaccines
    • 12.2.1 Status of vaccine development
  • 12.3 HIV Vaccine Development
  • 12.4 Meningitis Vaccine Development
  • 12.5 Influenza vaccines
    • 12.5.1 Influenza Vaccine Development
    • 12.5.2 Status of Vaccine Development
    • 12.5.3 Challenges to Vaccine Development
  • 12.6 Tuberculosis Vaccine Development
  • 12.7 Zika Virus Vaccine Product Development
    • 12.7.1 Technical roadmap for Zika vaccine development
  • 12.8 Group A Streptococcus
  • 12.9 RSV Vaccine Research And Development

13. Leading Company Profiles

  • 13.1 Recent Technologies and Companies
  • 13.2 Market Share
  • 13.3 AstraZeneca
    • 13.3.1 AstraZeneca: Business Overview
    • 13.3.2 AstraZeneca: Company Financial Profile
    • 13.3.3 AstraZeneca: Product and Service Offerings
    • 13.3.4 AstraZeneca: Recent Developments
  • 13.4 Johnson & Johnson
    • 13.4.1 Johnson & Johnson: Business Overview
    • 13.4.2 Johnson & Johnson: Company Financial Profile
    • 13.4.3 Johnson & Johnson: Product and Service Offerings
    • 13.4.4 Johnson & Johnson: Recent Developments
  • 13.5 Bavarian Nordic
    • 13.5.1 Bavarian Nordic: Business Overview
    • 13.5.2 Bavarian Nordic: Company Financial Profile
    • 13.5.3 Bavarian Nordic: Product and Service Offerings
    • 13.5.4 Bavarian Nordic: Recent Developments
  • 13.6 Merck & Co.
    • 13.6.1 Merck & Co.: Business Overview
    • 13.6.2 Merck & Co.: Company Financial Profile
    • 13.6.3 Merck & co.: Product and Service Offerings
    • 13.6.4 Merck & co.: Recent Developments
  • 13.7 Takeda Pharmaceutical Company
    • 13.7.1 Takeda Pharmaceutical Company: Business Overview
    • 13.7.2 Takeda Pharmaceutical Company: Company Financial Profile
    • 13.7.3 Takeda Pharmaceutical Company: Product and Service Offerings
    • 13.7.4 Takeda Pharmaceutical Company: Recent Developments
  • 13.8 Roche Holding AG
    • 13.8.1 Roche Holding AG: Business Overview
    • 13.8.2 Roche Holding AG: Company Financial Profile
    • 13.8.3 Roche Holding AG: Product and Service Offerings
    • 13.8.4 Roche Holding AG: Recent Developments
  • 13.9 GlaxoSmithKline PLC (GSK)
    • 13.9.1 GlaxoSmithKline PLC (GSK): Business Overview
    • 13.9.2 GlaxoSmithKline PLC (GSK): Company Financial Profile
    • 13.9.3 GlaxoSmithKline PLC (GSK): Product and Service Offerings
    • 13.9.4 GlaxoSmithKline PLC (GSK): Recent Developments
  • 13.10 Bayer Inc.
    • 13.10.1 Bayer Inc.: Business Overview
    • 13.10.2 Bayer Inc.: Company Financial Profile
    • 13.10.3 Bayer Inc.: Product and Service Offerings
    • 13.10.4 Bayer Inc.: Recent Developments
  • 13.11 Eli Lilly and Company
    • 13.11.1 Eli Lilly and Company: Business Overview
    • 13.11.2 Eli Lilly and Company: Company Financial Profile
    • 13.11.3 Eli Lilly and Company: Product and Service Offerings
    • 13.11.4 Eli Lilly and Company: Recent Developments
  • 13.12 Bristol-Myers Squibb
    • 13.12.1 Bristol-Myers Squibb: Business Overview
    • 13.12.2 Bristol-Myers Squibb: Company Financial Profile
    • 13.12.3 Bristol-Myers Squibb: Product and Service Offerings
    • 13.12.4 Bristol-Myers Squibb: Recent Developments
  • 13.13 Pfizer Inc.
    • 13.13.1 Pfizer Inc.: Business Overview
    • 13.13.2 Pfizer Inc.: Company Financial Profile
    • 13.13.3 Pfizer Inc.: Product and Service Offerings
    • 13.13.4 Pfizer Inc.: Recent Developments
  • 13.14 Emergent BioSolutions Inc.
    • 13.14.1 Emergent BioSolutions Inc.: Business Overview
    • 13.14.2 Emergent BioSolutions Inc.: Company Financial Profile
    • 13.14.3 Emergent BioSolutions Inc.: Product and Service Offerings
    • 13.14.4 Emergent BioSolutions Inc.: Recent Developments
  • 13.15 Fresenius SE & Co KGaA
    • 13.15.1 Fresenius SE & Co KGaA: Business Overview
    • 13.15.2 Fresenius SE & Co KGaA: Company Financial Profile
    • 13.15.3 Fresenius SE & Co KGaA: Product and Service Offerings
    • 13.15.4 Fresenius SE & Co KGaA: Recent Developments
  • 13.16 Sanofi
    • 13.16.1 Sanofi: Business Overview
    • 13.16.2 Sanofi: Company Financial Profile
    • 13.16.3 Sanofi: Product and Service Offerings
    • 13.16.4 Sanofi: Recent Developments
  • 13.17 BiondVaxPharmaceuticals Ltd.
    • 13.17.1 BiondVax Pharmaceuticals Ltd.: Business Overview
    • 13.17.2 BiondVax Pharmaceuticals Ltd.: Company Financial Profile
    • 13.17.3 BiondVax Pharmaceuticals Ltd.: Product and Service Offerings
    • 13.17.4 BiondVax Pharmaceuticals Ltd.: Recent Developments

14. Conclusion & Recommendations